Mobilization of Human Progenitors in NOD/SCID Mice
Group . | No. of Animals . | Treatment* . | n-Fold Increase Over Control† . | 95% Confidence Limits . | P Value‡ . |
---|---|---|---|---|---|
I | 5 | CY + G-CSF | nd | — | — |
II | 13 | pooled | 4.59 | (1.24, 17.0) | .019 |
8 | G-CSF | 5.60 | (1.63, 19.17) | .007 | |
5 | G-CSF + SCF | 1.82 | (0.45, 7.45) | .46 |
Group . | No. of Animals . | Treatment* . | n-Fold Increase Over Control† . | 95% Confidence Limits . | P Value‡ . |
---|---|---|---|---|---|
I | 5 | CY + G-CSF | nd | — | — |
II | 13 | pooled | 4.59 | (1.24, 17.0) | .019 |
8 | G-CSF | 5.60 | (1.63, 19.17) | .007 | |
5 | G-CSF + SCF | 1.82 | (0.45, 7.45) | .46 |
NOD/SCID mice were treated with various mobilization regimens 6 to 8 weeks after transplantation. Treatment regimens in (I): Cyclophosphamide (200 mg/kg) followed 2-days later by 4 days of G-CSF (250 μg/kg/day); in (II): treatment with G-CSF for 4 days (at 25 or 250 μg/kg/day), or with G-CSF (at 25 or 250 μg/kg/day) and pegylated-SCF (20 μg/kg/day) for 4 to 6 days.
Abbreviation: nd, not detected.
Group I shows the result of an individual experiment. In group II results have been combined. The group pooled includes all animals that received human G-CSF or SCF, whereas the other two groups show the combined result of all animals that were treated with either G-CSF alone or with G-CSF and SCF (at low or high dose) among the four experiments performed.
Differences between groups were statistically analyzed using a generalized linear model. Fold-increase over control indicates the mean fold-increase of the number of human progenitors found in the peripheral blood in animals treated with a mobilizing regimen as compared with the number of progenitors in untreated animals (n = 15).
The P value is based on the result of the generalized linear model and indicates the level of significance of the difference between treatment groups and control, adjusted for the number of cells injected per animal, the treatment regimen, and volume of blood collected.